S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
NASDAQ:RXST

RxSight - RXST Stock Forecast, Price & News

$16.07
+0.32 (+2.03%)
(As of 03/22/2023 02:34 PM ET)
Add
Compare
Today's Range
$15.48
▼
$16.47
50-Day Range
$12.58
▼
$15.75
52-Week Range
$9.78
▼
$16.99
Volume
141,536 shs
Average Volume
137,228 shs
Market Capitalization
$542.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67

RxSight MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
16.2% Upside
$18.67 Price Target
Short Interest
Healthy
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$6 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.29) to ($1.92) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

608th out of 983 stocks

Ophthalmic Goods Industry

6th out of 7 stocks

See Top Rated MarketRank™ Stocks Here

RXST stock logo

About RxSight (NASDAQ:RXST) Stock

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

RXST Stock News Headlines

March 13, 2023 | finance.yahoo.com
How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%
March 9, 2023 | msn.com
Looking Into RxSight's Return On Capital Employed
March 22, 2023 | Press Reach (Ad)
Stock Market Update
This stock is taking America by storm. Find out why it's trending right now.
March 8, 2023 | finance.yahoo.com
RxSight, Inc. (NASDAQ:RXST) Q4 2022 Earnings Call Transcript
March 7, 2023 | msn.com
5 Analysts Have This to Say About RxSight
March 7, 2023 | finance.yahoo.com
RxSight, Inc.'s (NASDAQ:RXST) biggest owners are individual investors who got richer after stock soared 14% last week
March 6, 2023 | finance.yahoo.com
RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
March 3, 2023 | markets.businessinsider.com
Needham Keeps Their Buy Rating on RxSight (RXST)
March 22, 2023 | Press Reach (Ad)
Stock Market Update
This stock is taking America by storm. Find out why it's trending right now.
March 3, 2023 | msn.com
Earnings Preview: RxSight
February 21, 2023 | finance.yahoo.com
RxSight, Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 6, 2023
February 8, 2023 | msn.com
Why RxSight Shares Are Plummeting
February 8, 2023 | finance.yahoo.com
RxSight, Inc. Announces Pricing of Public Offering of Common Stock
February 7, 2023 | msn.com
RxSight launches $40M stock offering
February 7, 2023 | finance.yahoo.com
RxSight, Inc. Announces Proposed Public Offering of Common Stock
January 9, 2023 | finance.yahoo.com
Investing in RxSight (NASDAQ:RXST) a year ago would have delivered you a 12% gain
January 8, 2023 | finance.yahoo.com
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results
December 31, 2022 | finance.yahoo.com
RxSight, Inc. (NASDAQ:RXST) Q3 2022 Earnings Call Transcript
December 28, 2022 | finance.yahoo.com
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
December 22, 2022 | finance.yahoo.com
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
December 6, 2022 | finance.yahoo.com
Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year?
December 3, 2022 | finance.yahoo.com
Does RxSight, Inc. (RXST) Have the Potential to Rally 43% as Wall Street Analysts Expect?
December 1, 2022 | msn.com
RxSight Earnings Perspective: Return On Capital Employed
November 16, 2022 | finance.yahoo.com
Wall Street Analysts Predict a 45% Upside in RxSight, Inc. (RXST): Here's What You Should Know
November 9, 2022 | finance.yahoo.com
RxSight Third Quarter 2022 Earnings: Beats Expectations
November 8, 2022 | seekingalpha.com
RxSight, Inc. (RXST) Q3 2022 Earnings Call Transcript
November 8, 2022 | finance.yahoo.com
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
See More Headlines
Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

RXST Company Calendar

Today
3/22/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Ophthalmic goods
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXST
CUSIP
N/A
CIK
1111485
Web
www.rxsight.com
Phone
949-521-7830
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.67
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+18.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-66,760,000.00
Net Margins
-136.22%
Pretax Margin
-136.20%
Return on Equity
-63.73%
Return on Assets
-41.10%

Debt

Debt-to-Equity Ratio
0.45
Current Ratio
7.81
Quick Ratio
6.95

Sales & Book Value

Annual Sales
$49.01 million
Price / Sales
10.86
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.24 per share
Price / Book
4.86

Miscellaneous

Outstanding Shares
33,780,000
Free Float
25,079,000
Market Cap
$532.04 million
Optionable
Not Optionable
Beta
0.37

Key Executives

  • Dr. Ronald M. Kurtz M.D. (Age 59)
    Pres, CEO & Director
    Comp: $851.06k
  • Ms. Shelley B. Thunen (Age 68)
    CFO & Assistant Sec.
    Comp: $536.65k
  • Dr. Ilya Goldshleger Ph.D. (Age 47)
    Chief Operating Officer
    Comp: $571.6k
  • Mr. Eric J. Weinberg (Age 61)
    Chief Commercial Officer
    Comp: $575.62k
  • Rebecca Williston
    VP of Accounting & Fin.
  • Mr. Matt Haller Ph.D.
    Chief Technology Officer
  • Steve Everly
    VP of US Sales
  • Mr. Roy Freeman
    VP of Marketing
  • Caroline Vaughn
    VP of HR
  • Scott Gaines
    Sr. VP of Commercial Operations & Bus. Process

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RXST Stock - Frequently Asked Questions

Should I buy or sell RxSight stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RXST shares.
View RXST analyst ratings or view top-rated stocks.

What is RxSight's stock price forecast for 2023?

4 Wall Street research analysts have issued 12 month price objectives for RxSight's shares. Their RXST share price forecasts range from $14.00 to $22.00. On average, they anticipate the company's share price to reach $18.67 in the next year. This suggests a possible upside of 18.5% from the stock's current price.
View analysts price targets for RXST or view top-rated stocks among Wall Street analysts.

How have RXST shares performed in 2023?

RxSight's stock was trading at $12.67 at the beginning of 2023. Since then, RXST shares have increased by 24.3% and is now trading at $15.75.
View the best growth stocks for 2023 here.

When is RxSight's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our RXST earnings forecast.

What guidance has RxSight issued on next quarter's earnings?

RxSight issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $78.00 million-$83.00 million, compared to the consensus revenue estimate of $76.70 million.

When did RxSight IPO?

(RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share.

What is RxSight's stock symbol?

RxSight trades on the NASDAQ under the ticker symbol "RXST."

Who are RxSight's major shareholders?

RxSight's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.42%), Geode Capital Management LLC (1.10%), Point72 Asset Management L.P. (0.93%), Russell Investments Group Ltd. (0.25%), Charles Schwab Investment Management Inc. (0.19%) and Schonfeld Strategic Advisors LLC (0.17%). Insiders that own company stock include Bakker Juliet Tammenoms and Jesse Anderson Corley.
View institutional ownership trends.

How do I buy shares of RxSight?

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RxSight's stock price today?

One share of RXST stock can currently be purchased for approximately $15.75.

How much money does RxSight make?

RxSight (NASDAQ:RXST) has a market capitalization of $532.04 million and generates $49.01 million in revenue each year. The company earns $-66,760,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does RxSight have?

The company employs 2,021 workers across the globe.

How can I contact RxSight?

The official website for the company is www.rxsight.com. The company can be reached via phone at 949-521-7830 or via email at ir@rxsight.com.

This page (NASDAQ:RXST) was last updated on 3/22/2023 by MarketBeat.com Staff